ArticleCurrent Alzheimer research2014
Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.
Article in Current Alzheimer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Can IVIG Intervene in AD? Insights from Animal Experiments and Clinical Trials-A Systematic Review and Synthesis Without Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease.Current Alzheimer research · 2016Pooled it
- Harnessing chimeric antigen receptor (CAR)-T cells as a potential treatment for Alzheimer's disease.Cell & gene therapy insights · 2023Article
- IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease.Molecular neurobiology · 2019Article
- Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer's Disease.Current Alzheimer research · 2019Article
- Induced dural lymphangiogenesis facilities soluble amyloid-beta clearance from brain in a transgenic mouse model of Alzheimer's disease.Neural regeneration research · 2018Article
- Optimizing early Go/No Go decisions in CNS drug development.Expert review of clinical pharmacology · 2015Article
- The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence.Neuropsychiatric disease and treatment · 2015Review
- Toxic species in amyloid disorders: Oligomers or mature fibrils.Annals of Indian Academy of NeurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.